S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-specific anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in other tissues such as in the prostate gland, thus avoiding side effects such as benign prostatic hypertrophy which can occur following treatment with unselective androgens like testosterone or anabolic steroids. References: Thevis M, Schanzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2017 Jan 27. pii: S0303-7207(17)30053-9. doi: 10.1016/j.mce.2017.01.040. [Epub ahead of print] PubMed PMID: 28137616.

纯度：≥98%

CAS：404920-28-1